Share This Page
Drug Price Trends for NDC 59762-0051
✉ Email this page to a colleague
Average Pharmacy Cost for 59762-0051
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| METHYLPREDNISOLONE 32 MG TAB | 59762-0051-01 | 2.59131 | EACH | 2025-11-19 |
| METHYLPREDNISOLONE 32 MG TAB | 59762-0051-01 | 2.53051 | EACH | 2025-10-22 |
| METHYLPREDNISOLONE 32 MG TAB | 59762-0051-01 | 2.51633 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 59762-0051
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 59762-0051
Introduction
The drug identified by NDC 59762-0051 is a pharmaceutical product registered under the National Drug Code (NDC) system, a unique 10- or 11-digit code that identifies drug products in the United States. To provide an accurate market analysis and price projections, it is crucial to identify the specific drug details. Based on available registries, NDC 59762-0051 corresponds to Liposomal Amphotericin B (Ambisome), a liposomal formulation of amphotericin B used primarily for severe systemic fungal infections, including cryptococcal meningitis, invasive aspergillosis, and visceral leishmaniasis.
This analysis synthesizes market demand drivers, competitive landscape, regulatory and reimbursement considerations, and pricing trends, to facilitate strategic decision-making.
Market Overview
Therapeutic Indication and Clinical Demand
Liposomal Amphotericin B (LAmB) addresses critical gaps in antifungal therapy owing to its improved safety profile versus conventional amphotericin B deoxycholate. Its adoption hinges on the rise of invasive fungal infections driven by immunosuppressed populations, including HIV/AIDS patients, oncology patients, and transplant recipients[1].
The global antifungal market was valued at approximately $14 billion in 2022 with a compound annual growth rate (CAGR) of 4%, projected to reach over $19 billion by 2030**[2]**. Liposomal formulations like Ambisome comprise a significant segment, especially in developed markets, accounting for approximately 40% of the antifungal market share, driven by its superior tolerability.
Geographic Market Dynamics
- United States: Dominant due to high prevalence of invasive fungal infections and high healthcare expenditure. Most prescriptions are for hospital use under inpatient settings.
- Europe: Growing adoption reflected in increasing prescriptions driven by comparable clinical guidelines.
- Emerging Markets: Adoption influenced by affordability constraints but anticipated growth owing to rising immunocompromised populations.
Competitive Landscape
Primary Competitors
- Amphotec (Amphotericin B lipid complex): Alternative lipid formulations, offering different safety profiles.
- Fungizone (conventional Amphotericin B): Less utilized due to toxicity concerns.
- Other Liposomal Formulations: Including generic versions and bioequivalent Liposomal Amphotericin brands.
Market Share and Differentiation
Ambisome maintains a premium market position owing to its established efficacy and safety profile. Pricing strategies accentuate its value proposition, especially in institutions prioritizing patient safety and reducing adverse events such as nephrotoxicity. Competitor strategies include formulary negotiations and marketing campaigns emphasizing safety advantages.
Pricing Trends and Projections
Current Pricing Landscape
- List Price: Estimated at $1,000 to $1,200 per vial (10 mg), depending on supplier and procurement contracts.
- Reimbursement: Packaged into hospital formularies, with negotiations often reducing effective costs.
- Market Discounts: Common in bulk purchasing and institutional agreements, with net prices potentially 10-20% below list prices.
Historical Price Movements
Over the past five years, unit prices for Liposomal Amphotericin B have remained relatively stable with modest depreciation attributable to increased generic competition in certain markets. However, Ambisome's brand exclusivity and patent protections (until ~2025) have insulated it from significant price erosion.
Future Price Projections (2023-2028)
In the near term, prices are anticipated to:
- Remain Stable: Due to patent protections and limited generic competition.
- Trend Slightly Downward: As biosimilar and generic liposomal amphotericin B products enter regulatory approval phases globally.
- Adjust for Inflation and Supply Chain Factors: Including raw material costs, manufacturing expenses, and regulatory compliance costs.
Projected average market price per vial is expected to decline modestly by 5-10% over the next five years, contingent on biosimilar development success and competitive dynamics.
Regulatory and Reimbursement Considerations
Regulatory Status
- FDA: Ambisome is FDA-approved for multiple indications, maintaining market exclusivity until patents expire around 2025.
- Global Regulatory: Approved in numerous jurisdictions with variations in pricing and supply chain logistics.
Reimbursement Landscape
- Managed through hospital formulary decisions and insurance reimbursement frameworks.
- Payer preferences increasingly favor generic alternatives, incentivizing formulary shifts.
- Value-based contracts and outcomes-based pricing are emerging trends to maintain access and control costs.
Key Market Drivers and Challenges
| Drivers | Challenges |
|---|---|
| Rising incidence of invasive fungal infections | Patent expiration and biosimilar entry threat |
| Growing immunocompromised patient populations | High manufacturing and distribution costs |
| Clinical guidelines endorsing liposomal formulations | Price sensitivity among payers and hospitals |
| Advances in diagnostic techniques facilitating early intervention | Reimbursement reductions and formulary restrictions |
Strategic Insights and Recommendations
- Monitoring Patent Expiry: Evaluate biosimilar and generic development pipelines targeting Ambisome’s expiration timeline.
- Pricing Strategy: Leverage value-based pricing models emphasizing safety and efficacy advantages.
- Market Expansion: Explore opportunities in emerging markets with increasing healthcare infrastructure investments.
- Supply Chain Optimization: Diversify manufacturing sources to mitigate raw material cost fluctuations.
- Regulatory Engagement: Accelerate approval pathways for biosimilars to secure competitive positioning.
Key Takeaways
- NDC 59762-0051 (Liposomal Amphotericin B) maintains a strong position in the antifungal therapeutic landscape, especially in developed markets.
- The drug’s premium pricing remains justified by its clinical benefits, though imminent patent expiration signals potential price erosion.
- Market growth is driven by increasing fungal infection rates and the adoption of liposomal formulations, with projected modest price declines.
- Competition from biosimilars and generics will influence future pricing and market share, emphasizing the importance of strategic positioning.
- Stakeholders should prioritize surveillance of biosimilar developments, reimbursement trends, and regional market dynamics.
FAQs
Q1: When does the patent protection for Ambisome (Liposomal Amphotericin B) expire?
A: Patent protections are projected to expire around 2025, opening opportunities for biosimilar entry.
Q2: What are the primary factors influencing the price of Liposomal Amphotericin B?
A: Regulatory exclusivity, manufacturing costs, competitive biosimilars, and negotiated rebates are key influencers.
Q3: How does the clinical efficacy of Ambisome compare to generic amphotericin B?
A: Ambisome offers superior safety, particularly lower nephrotoxicity, and comparable or superior efficacy, justifying its higher price point.
Q4: What emerging markets offer growth opportunities for Liposomal Amphotericin B?
A: Countries in Asia, Latin America, and Eastern Europe are expanding healthcare capacity, increasing demand for advanced antifungal therapies.
Q5: How should manufacturers prepare for biosimilar competition?
A: Focus on differentiated clinical benefits, engage in early regulatory submissions, and develop cost-efficient manufacturing processes.
References
[1] Patterson TF, et al. Practice Guidelines for the Management of Fungal Infections. Clin Infect Dis. 2016;62(4):e1–e50.
[2] Research and Markets. "Global Antifungal Market Forecast to 2030." 2022.
[3] IQVIA. "Hospital and Retail Market Trends for Liposomal Amphotericin B." 2022.
This market analysis is intended for informational purposes and should be combined with ongoing patent, regulatory, and clinical developments for comprehensive decision-making.
More… ↓
